SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharma discovers new anti-cancer molecule

01 Apr 2011 Evaluate

Glenmark Pharmaceuticals has announced the discovery of a new molecule for oncology treatment and would file an application for phase-I trials in the fourth quarter of FY12. Developed at Glenmark's Switzerland-based research centre, the GBR 401 molecule is an anti-CD19 monoclonal antibody primarily targeted for treating lymphoma and leukemia of B-cell origin. In addition, the molecule also has potential to treat disorders like rheumatoid arthritis. The molecule is in the same segment of anti-cancer biotech product rituximab, which had annual global sales of $6 billion.crackcrack

Glenmark Pharma Share Price

2155.60 -17.60 (-0.81%)
15-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.45
Dr. Reddys Lab 1279.25
Cipla 1381.50
Zydus Lifesciences 1087.75
Lupin 2273.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: